**Appendix Table C101. Outcome assessment: Comparator, autoimmune disease**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study (Investigator,**  **country, year)** | **Record Number** | **Group (N)** | **Primary Outcomes** | **F/U Frequency/Duration** |
| Crino et al, Italy, 2005 | 62110 | nicotinamide plus intensive insulin therapy (25) intensive insulin therapy only (27) | glycosylated hemoglobin (%) 0, 12, 24 mos fasting C-peptide (nmol/L) 0, 12, 24 mos | nicotinamide plus intensive insulin therapy 9.6+/-2.2, 5.4+/-0.8, 6.1+/-0.9, 1.9+/-0.15, 0.25+/-0.2, 0.19+/-0.2 intensive insulin therapy 10.5+/-2.2, 6.5+/-0.9, 7.0+/-0.9, 0.16+/-0.12, 0.21+/-0.2, 0.19+/-0.13 |
| Mastrandrea et al, USA, 2009 | 40050 | etanercept plus intensive insulin therapy (10) | glycosylated hemoglobin (%) 0, 24 wks meal stimulated C peptide AUC (ng/mL/hr) 0, 24 wks | 12.8+/-3.2, 5.9+/-0.5 3.1+/-1.2 ng/mL/hr, 3.9+/-1.6 ng/mL/hr |